Chengdu Kanghua Biological Products Co Ltd Class A 300841
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Trading Information
- Previous Close Price
- CNY 55.40
- Day Range
- CNY 54.40–55.92
- 52-Week Range
- CNY 44.78–84.05
- Bid/Ask
- CNY 55.79 / CNY 55.94
- Market Cap
- CNY 7.53 Bil
- Volume/Avg
- 1.6 Mil / 2.0 Mil
Key Statistics
- Price/Earnings (Normalized)
- 12.57
- Price/Sales
- 4.64
- Dividend Yield (Trailing)
- 3.58%
- Dividend Yield (Forward)
- 3.58%
- Total Yield
- 3.58%
Company Profile
Chengdu Kanghua Biological Products Co Ltd is engaged in research, development, production, sales and technical services of biological products for prevention, and the existing products include Group ACYW135 Meningococcal Polysaccharide Vaccine-Maikexin, Rabies Vaccine (human diploid cell) for Human Use, freeze-dried - HDCV. The company's products include ACYW135 Meningococcal Polysaccharide Vaccine; and Rabies Vaccine.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Mid Core
- Total Number of Employees
- 672
- Website
- https://www.kangh.com
Comparables
Valuation
|
Metric
|
300841
|
300601
|
02179
|
|---|---|---|---|
Price/Earnings (Normalized) | 12.57 | 33.89 | — |
Price/Book Value | 2.09 | 1.94 | 4.70 |
Price/Sales | 4.64 | 5.80 | — |
Price/Cash Flow | 11.40 | 22.29 | — |
Price/Earnings
300841
300601
02179
Financial Strength
|
Metric
|
300841
|
300601
|
02179
|
|---|---|---|---|
Quick Ratio | 4.14 | 1.36 | 3.86 |
Current Ratio | 4.49 | 1.82 | 3.99 |
Interest Coverage | 119.95 | 6.43 | −84.89 |
Quick Ratio
300841
300601
02179
Profitability
|
Metric
|
300841
|
300601
|
02179
|
|---|---|---|---|
Return on Assets (Normalized) | 15.03% | 3.75% | −23.96% |
Return on Equity (Normalized) | 17.64% | 5.79% | −46.33% |
Return on Invested Capital (Normalized) | 16.65% | 4.61% | −30.73% |
Return on Assets
300841
300601
02179
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc
VRTX
| Xzyksdf | Pzjrm | $124.1 Bil | |||
| Regeneron Pharmaceuticals Inc
REGN
| Bjbwswry | Dvryctk | $114.2 Bil | |||
| Moderna Inc
MRNA
| Ljymdxq | Msh | $53.7 Bil | |||
| argenx SE ADR
ARGX
| Fdkzgkztz | Hhbr | $23.0 Bil | |||
| BioNTech SE ADR
BNTX
| Kstjzhllj | Slj | $22.2 Bil | |||
| Alnylam Pharmaceuticals Inc
ALNY
| Rshztxzlf | Hcpbhb | $20.3 Bil | |||
| Biomarin Pharmaceutical Inc
BMRN
| Fgclfhvn | Xmfpn | $15.9 Bil | |||
| United Therapeutics Corp
UTHR
| Bkmdklg | Rvqc | $12.8 Bil | |||
| Incyte Corp
INCY
| Fcwsxfy | Ngnxf | $12.2 Bil | |||
| Royalty Pharma PLC Class A
RPRX
| Gbtnjytlf | Ysbbj | $12.2 Bil |